Key result
Longer-term use of ACE inhibitors or CCBs was not associated with an altered risk of developing breast cancer compared with nonusers.
Why the study?
Does previous exposure to ACE inhibitors, calcium channel blockers, or beta-blockers affect the risk of developing breast cancer in postmenopausal women?
Case-Control (n=17,861)
Does previous exposure to ACE inhibitors, calcium channel blockers, or beta-blockers affect the risk of developing breast cancer in postmenopausal women?
Long-term use of common antihypertensive medications, including ACE inhibitors, calcium channel blockers, and beta-blockers, does not affect the risk of developing breast cancer in postmenopausal women.
Answers are grounded in this paper and cite their sources.
Observational data show no breast cancer link with ACE inhibitors or CCBs; leaves open need for prospective confirmation.
BACKGROUND: The use of angiotensin-converting enzyme (ACE) inhibitors has been linked to a decreased risk of developing cancer, and longer-term use of calcium channel blockers (CCBs) has been associated with an increased risk of developing cancer in general and breast cancer in particular. METHODS: Using data from the General Practice Research Database, we conducted a large case-control analysis. Previous exposure to ACE inhibitors, CCBs, and beta-blockers was compared between 3706 postmenopausal women who were diagnosed with incident breast cancer between 1992 and 1997 and 14155 matched-control women. RESULTS: Compared with nonusers of antihypertensive drugs, women who used ACE inhibitors (odds ratio [OR], 1.0; 95% confidence interval [CI], 0.7-1.5), CCBs (OR, 0.9; 95% CI, 0.7-1.2), or beta-blockers (OR, 1.0; 95% CI, 0.8-1.2) for 5 or more years were not at an increased or decreased risk of developing breast cancer (adjusted for smoking and body mass index [calculated as weight in kilograms divided by the square of height in meters]). The risk of breast cancer did not differ between users of different ACE inhibitors or different CCBs (dihydropyridines, diltiazem hydrochloride, and verapamil hydrochloride) or between users of short-acting (OR, 1.0; 95% CI, 0.7-1.4) or sustained-release (OR, 1.0; 95% CI, 0.8-1.3) nifedipine preparations. CONCLUSION: The findings of this large case-control analysis do not support the hypothesis that longer-term use of ACE inhibitors or CCBs affects the risk of developing breast cancer.
No takes yet. Share an insight, caveat, or question.
Meier et al. (2000) conducted a case-control in Breast cancer (n=17,861). ACE inhibitors and calcium channel blockers vs. Nonusers of antihypertensive drugs was evaluated on Incident breast cancer (OR 1.0, 95% CI 0.7-1.5). Longer-term use of ACE inhibitors or CCBs was not associated with an altered risk of developing breast cancer compared with nonusers.
Synapse has enriched 10 related papers. Consider them for comparative context: